ORMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ORMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Oramed Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 was $2.61.
The historical rank and industry rank for Oramed Pharmaceuticals's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Oramed Pharmaceuticals was 173.00. The lowest was 0.87. And the median was 4.59.
The historical data trend for Oramed Pharmaceuticals's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oramed Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Aug14 | Aug15 | Aug16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Dec22 | Dec23 | |||||||||||
Net Cash per Share | Get a 7-Day Free Trial | 0.98 | 1.19 | 2.32 | 3.69 | 2.61 |
Oramed Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Feb19 | May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Net Cash per Share | Get a 7-Day Free Trial | 3.69 | 3.63 | 3.62 | 2.32 | 2.61 |
For the Biotechnology subindustry, Oramed Pharmaceuticals's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Oramed Pharmaceuticals's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Oramed Pharmaceuticals's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as
Net Cash per Share (A: Dec. 2023 ) | |||||||
= | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (162.047 | - | 57.658 | - | -0.928) | / | 40.339 |
= | 2.61 |
Oramed Pharmaceuticals's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as
Net Cash per Share (Q: Dec. 2023 ) | = | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (162.047 | - | 57.658 | - | -0.928) | / | 40.339 |
= | 2.61 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oramed Pharmaceuticals (NAS:ORMP) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Benjamin Shapiro | director | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
Nadav Kidron | director, 10 percent owner | 142 W. 57TH ST., NEW YORK NY 10019 |
Yadin Rozov | director | 9 TERRACE CIRCLE, ARMONK NY 10504 |
Miriam Kidron | director | 2 ELZA STREET, JERUSALEM L3 93706 |
Michael Rabinowitz | officer: Chief Commercial Officer | 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036 |
Arie Mayer | director | MORAN 16, KFAR SABA L3 4428890 |
Netanel Derovan | officer: Chief Legal Officer | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036 |
David Silberman | officer: Chief Financial Officer | 20 MAMILLA AVENUE, JERUSALEM L3 9414904 |
Kevin Rakin | director | 36 CHURCH LANE, WESTPORT CT 06880 |
Michael Rabinowitz | officer: Chief Commercial Officer | MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174 |
Leonard Sank | director | 3 BLAIR ROAD, CAPE TOWN T3 8005 |
Gao Xiaoming | director | 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001 |
Avraham Gabay | officer: CFO, Treasurer and Secretary | 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390 |
Mark Daniel Hasleton | officer: VP Business Development | 13, HIBAT ZION, RAANANA, RAANANA L3 4338111 |
Aviad Friedman | director | HADASSA 6, TEL AVIV L3 6451306 |
From GuruFocus
By PRNewswire PRNewswire • 11-09-2022
By PRNewswire PRNewswire • 12-21-2022
By PRNewswire PRNewswire • 02-09-2023
By PRNewswire • 08-02-2023
By PRNewswire PRNewswire • 05-18-2023
By PRNewswire PRNewswire • 07-07-2022
By PRNewswire PRNewswire • 06-23-2022
By PRNewswire PRNewswire • 07-13-2022
By PRNewswire PRNewswire • 07-03-2022
By PRNewswire PRNewswire • 07-07-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.